Eisai Of Japan To Face Alzheimer's Competition As Others Gear Up
This article was originally published in PharmAsia News
Japan's Eisai could face competition from Daiichi Sankyo and Switzerland's Novartis for drugs to treat Alzheimer's disease
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.